The global bioconjugation market is set to witness a growth rate of ~13% in the next 5 years. Increasing demand for targeted ...
Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded from4-26, 2025. The conference brought together leading biopharmaceutical companies and research ...
Preclinical data presented at the 10th Annual CAR-TCR Summit demonstrated deep depletion of B cells in blood and tissue in humanized mouse models and non-human primates, supporting nomination of ...
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy ...
Pharmaceutical Technology on MSN
Synaffix and Qurient enter licensing deal for dual-payload ADC
Synaffix has entered a licensing agreement with South Korean biopharmaceutical firm Qurient to develop a dual-payload ADC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback